Seeking Alpha

AstraZeneca (AZN +0.8%) ticks higher after presenting final overall survival analysis on...

AstraZeneca (AZN +0.8%) ticks higher after presenting final overall survival analysis on Faslodex, which showed a 4.1 month difference in median overall survival when using Faslodex Injection 500 mg compared with 250 mg. Faslodex is a treatment for metastatic breast cancer in postmenopausal women. The findings were presented today at the 35th CTRC-AACR San Antonio Breast Cancer Symposium.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs